The best medicine for 2020: The Finger Awards by Comedy for Change

If laughter is the best medicine, the Finger Awards sponsored by the organization Comedy for Change will be particularly welcome this year.The awards will be presented in a virtual ceremony as part of the British Television conference. It will be broadcast live on December 4 on Content London at 4 p.m. GMT.“We had over 100 candidates this year and we are going to give a special award for COVID-19 projects. There are some surprisingly strong candidates from Vietnam, Bahrain, and Pakistan,” said Omri Marcus, the director of the competition and the founder of Comedy for Change, which spotlights comedy that is both funny and enlightening.British comedian and former TV executive Cally Beaton will host Friday’s online ceremony. Beaton has incredibly funny Twitter and Instagram feeds, which are worth checking out if you need something to laugh about.Ricky Gervais will receive an award for his contribution to comedy, an honor he will likely refer to as “getting the Finger.”Among this year’s finalists are “Medical Bill Art,” a clip from by MSCHF that shows medical bills made into paintings, which were sold for over $73,000 in order to pay, what else? – medical bills.“Naked Ballots” by RepresentUS in the US features naked celebrities – including Sarah Silverman, Josh Gad and Sacha Baron Cohen as Borat (who actually appears fully clothed) – urging voters to mail in their ballots right away.

Other finalists’ clips lampoon the coronavirus crisis, including a Vietnamese film that features the Corona Dance, which raises awareness of the need for hand washing, and “Stay at Home” from Bahrain, which features pajama-clad people who have won medals for performing mundane tasks at home.Marcus was a writer on the comedy series Eretz Nehederet when he was in his early 20s and has written for and created several comic and reality series. He is also the head of Screenz Originals, a global company that creates entertainment-driven, interactive customer experiences, and he volunteers as head of publicity for Eye from Zion, a humanitarian organization that performs free surgeries in Third World countries. The organization, established by his father in 2007, has saved the sight of hundreds of people (mainly children) around the world.His motto is, “Changing the world, one joke at a time.”

Source Article

Read more

Examining ancient healers in ‘The Invention of Medicine: From Homer to Hippocrates’

Raquel Aparicio for The Boston Globe

Doctors still invoke the Hippocratic Oath, which classics scholar Robin Lane Fox refers to as “the essential ethic of Western medicine” (although, as he characteristically points out, its actual links to Hippocrates are “eminently questionable”). As his new book, “The Invention of Medicine: From Homer to Hippocrates,” makes clear, these roots run deep.

As far back as we look in Western literature, we find doctors and medicine. Medical reflections litter the writings of Herodotus and Thucydides, and in the world of Homer doctors were so prized that the Greeks’ main doctor, Machaon, is considered by the Trojans to be a high-value target. These were the professionals, the men who made the ritual propitiations, read and interpreted the signs, and even sometimes got their hands bloody with actual injuries and disorders.

And it isn’t just these characters, it’s Homer himself. Anyone who’s ever read the many action sequences in the Iliad will have a vivid recollection of how gruesomely specific the poet could be when describing the violent deaths of his characters. The author of the Iliad may not have known about germ theory, but he certainly knew all the specific ways a spear could rip out your spleen.

“‘Doctor Homer’ continues to be discovered by surgeons and pathologists,” Lane Fox writes. “They count and tabulate Homeric wounds as data (53 in heads and necks or 54 thoracic, of which 70.17 per cent are fatal …) and continue to claim Homer as a surgeon like themselves.”

“The Invention of Medicine” is in part a very erudite detective story in which the author uses the tools of archeology and philology to shed light on a “remarkable doctor and thinker” who was active around the Hellespont in the last years of the fifth century BCE, a figure whose travels and insights are reflected in some of the documents of the Hippocratic Corpus of ancient medical lore. “Among his patients, our doctor attended citizens whose names match the names of men known to have been at the very top of their local society,” Lane Fox writes. “Such people could admit him, lodge him and pay for him, although his text never mentions fees.”

But these textual investigations are likely of more interest to Lane Fox’s fellow classicists than they are to the general reader, who’ll tend to be far more absorbed in the other major narrative strand that runs through the book: the excavation of the early, groping history of medicine as a craft.

We see these beginnings reflected in little shards and moments drawn from the Epidemics, a mid-first century BCE collection of medical knowledge. We see murky mysticism doing its best to fill the role that systematic science would perform 20 centuries later; we see raw practicalities offering some definitive answers but virtually nothing in the way of comfort; we see, looking out at us everywhere from these ancient records, the cases and sometimes even the names of long-dead sufferers, and, thanks to Lane Fox’s

Read more

Development of new stem cell type may lead to advances in regenerative medicine

IMAGE

IMAGE: Drs. Jun Wu, Leqian Yu, Yulei Wei and colleagues isolated a new type of pluripotent stem cell from mice, horses, and humans, named XPSCs, which are capable of generating chimeras…
view more 

Credit: Photo illustration by Leqian Yu

DALLAS – Dec. 3, 2020 – A team led by UT Southwestern has derived a new “intermediate” embryonic stem cell type from multiple species that can contribute to chimeras and create precursors to sperm and eggs in a culture dish.

The findings, published online this week in Cell Stem Cell, could lead to a host of advances in basic biology, regenerative medicine, and reproductive technology.

Cells in early embryos have a range of distinct pluripotency programs, all of which endow the cells to create various tissue types in the body, explains study leader Jun Wu, Ph.D., assistant professor of molecular biology. A wealth of previous research has focused on developing and characterizing “naïve” embryonic stem cells (those about four days post-fertilization in mice) and “primed” epiblast stem cells (about seven days post-fertilization in mice, shortly after the embryo implants into the uterus).

However, says Wu, there’s been little progress in deriving and characterizing pluripotent stem cells (PSCs) that exist between these two stages – largely because researchers have not been able to develop a paradigm for maintaining cells in this intermediate state. Cells in this state have been thought to possess unique properties: the ability to contribute to intraspecies chimeras (organisms that contain a mix of cells from different individuals of the same species) or interspecies chimeras (organisms that contain a mix of cells from different species) and the ability to differentiate into primordial germ cells in culture, the precursors to sperm and eggs.

For this study, the researchers successfully created intermediate PSCs, which they named “XPSCs” from mice, horses, and humans.

Wu says that these results could eventually lead to an array of advances in both basic and applied research. For example, looking at gene activity in XPSCs from different species and interspecies chimeras could help researchers understand which signatures have been conserved through evolution. Examining the communication between cells in chimeras may help scientists identify strategies that could be used to accelerate the development of tissues and organs from stem cells used for transplantation. And using chimera-derived primordial germ cells to create sperm and eggs could aid in preserving endangered animal species and advancing infertility treatments.

“These XPSCs have enormous potential. Our study helps open the door to each of these possibilities,” says Wu, who is a Virginia Murchison Linthicum Scholar in Medical Research.

Wu notes that developing XPSCs presented a special challenge because the conditions that keep naïve PSCs in a stable state are exactly the opposite from those that stabilize primed PSCs. While culture conditions for naïve PSCs must activate a WNT cell-signaling pathway and suppress the FGF and TGF-ß pathways, the conditions to maintain primed PSCs must suppress WNT and activate FGF and TGF-ß.

Aiming for the preferred environment for XPSC derivation, Wu and his

Read more

Health data company expands in Stamford as demand grows for genetic research and personal medicine

Sema4, a health data research company, announced Thursday it opened a 70,000-square foot building in Stamford with more than 300 workers processing genomic tests, its third site in Connecticut to keep pace with growing demand for data-driven health care.

The Stamford laboratory complements Sema4 1/4 u2032s Branford lab that was expanded earlier this year and its headquarters, also in Stamford.

The new Sema4 lab replaces one in New York City, providing additional capacity to support genomic testing and expand digital health services. With its Stamford and Branford labs, Sema4 will increase its ability to provide health information across several thousand genetically identifiable diseases to patients.

Eric Schadt, founder and chief executive of Sema4, said the new Stamford site will be a hub for research and development for predictive modeling and information-driven testing.

In addition to lab employees, the Stamford facility also has capacity for 100 genetic counselors, bioinformatics specialists and support service staff. Sema4 has more than 500 employees in Connecticut across its two lab facilities and Stamford headquarters. Its workforce has quadrupled over the last three years.

Sema4 also maintains an office in New York City.

The company’s growth reflects rapid advances in personal medicine and genomics, which focuses on sequencing and analyzing an organism’s genome, the DNA content in a cell.

The state announced in 2018 a $6 million loan to Sema4 to move its New York City laboratory to Connecticut and create 400 jobs. “We were kind of busting at the seams,” Schadt said at the time.

In Connecticut, Sema4 is part of an expanding cluster of medical technology companies, such as Arvinas, a New Haven cancer pharmaceutical company, and the Guilford medical device company Butterfly Network.

Stephen Singer can be reached at [email protected]

———

©2020 The Hartford Courant (Hartford, Conn.)

Visit The Hartford Courant (Hartford, Conn.) at www.courant.com

Distributed by Tribune Content Agency, LLC.

Continue Reading

Source Article

Read more

Thanks To The UN, Cannabis Is Now Officially A ‘Medicine’ & People Are Like ‘Der Aaye Par Durust Aaye’

The entire hullabaloo around drugs and narcotics has put a fair section of Indian youth at an edge. Times have been pretty unpredictable for those who like to take the ‘high’ ground (pun intended) in the way they lead their lives. With the authorities taking a good sniff at the many “underground” drug cartels operating in the country, talk about drugs and narcotics even as means of laughter can be pretty risky



a man talking on a cell phone: © Pexels


© Provided by MensXP
© Pexels

But, you know us. None of that can stop us from reporting on real ‘developments’ that are happening out there. And the most recent news is that cannabis is now officially a medicine. We already know that cannabis has been used therapeutically for thousands of years, but it was today that a historic vote at the United Nations finally recognised the medicinal value of cannabis and removed it from a list of dangerous drugs which are placed under the strictest controls.



© Pexels


© Provided by MensXP
© Pexels

The vote was made after experts at the World Health Organisation recommended that the UN’s Commission for Narcotic Drugs remove cannabis from an international list of dangerous drugs which are discouraged from being used for medicinal purposes. But there’s still a catch. While it’s recognised as a medicine, the UN stated that it still remains banned for non-medical use.

Yet, this sure comes as a welcome news for those who have been rallying for such a reform for a while now. So let’s check out what people have to say about it.

Read more

Weight Reduction Medicine Market Growth Boosters, Technological Advancements And New Products 2021-2026

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (AmericaNewsHour) —
Covering the growth of the Weight Reduction Medicine Market in regions- North America, Latin America, Europe, Asia Pacific and Middle East & Africa region, the research analysts at Kenneth Research have compiled a study in order to understand the latest industry trends and opportunities that are expected to influence the expansion of the market over the next ten years. The detailed report encloses the information on production, demand and consumer analysis related to overall consumption of the product.

The report covers the forecast and analysis of the Weight Reduction Medicine Market on a global and regional level. The study provides historical data from 2013 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints of the Weight Reduction Medicine Market along with the impact they have on the demand over the forecast period.

Click Here to Download Sample Report >>  https://www.kennethresearch.com/sample-request-10244417

Market Overview

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Weight Reduction Medicine by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
        Liauid
        Tablets
Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.):
        Roche
        GSK group
        Teva
        Sandoz(Novartis)
        STADA-VN J.V.Co., Ltd
        Hexal AG
        National Company For Pharmaceutical Industry
        Lunan Pharmaceutical Group Corporation
        Zein Pharmaceutical
        Hisun
        Taj Pharmaceuticals Ltd
        Kabir Life Sciences & Research
        Dm Pharma
        China Zhongshan Pharm
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
        Weight-reducing Aid
        Others
Region Coverage (Regional Production, Demand & Forecast by Countries etc.):
        North America (U.S., Canada, Mexico)
        Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
        Asia-Pacific (China, India, Japan, Southeast Asia etc.)
        South America (Brazil, Argentina etc.)
        Middle East & Africa (Saudi Arabia, South Africa etc.)

Request For Full Report >>https://www.kennethresearch.com/sample-request-10244417

Competitive Analysis:
The Weight Reduction Medicine Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included in this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.

Key points covered in this report:
? The historical and current data is provided in the report based on which the future projections are made and the industry analysis is performed.
? The import and export details along with consumption value and production capability of every region is mentioned in the report.
? Porter’s five forces analysis, value chain analysis,

Read more

Cannabis Officially Becomes A ‘Medicine’ & It’s All Thanks To A Historic UN Vote

The entire hullabaloo around drugs and narcotics has put a fair section of Indian youth at an edge. Times have been pretty unpredictable for those who like to take the ‘high’ ground (pun intended) in the way they lead their lives. With the authorities taking a good sniff at the many “underground” drug cartels operating in the country, talk about drugs and narcotics even as means of laughter can be pretty risky

Thanks To The UN, Cannabis Is Now Officially A ‘Medicine’© Pexels

But, you know us. None of that can stop us from reporting on real ‘developments’ that are happening out there. And the most recent news is that cannabis is now officially a medicine. We already know that cannabis has been used therapeutically for thousands of years, but it was today that a historic vote at the United Nations finally recognised the medicinal value of cannabis and removed it from a list of dangerous drugs which are placed under the strictest controls.

Thanks To The UN, Cannabis Is Now Officially A ‘Medicine’© Pexels

The vote was made after experts at the World Health Organisation recommended that the UN’s Commission for Narcotic Drugs remove cannabis from an international list of dangerous drugs which are discouraged from being used for medicinal purposes. But there’s still a catch. While it’s recognised as a medicine, the UN stated that it still remains banned for non-medical use.

Yet, this sure comes as a welcome news for those who have been rallying for such a reform for a while now. So let’s check out what people have to say about it.

Read more

3 Psychedelic Stocks to Invest In the Future of Medicine

InvestorPlace – Stock Market News, Stock Advice & Trading Tips

Psychedelic drugs are going mainstream fast, with research supporting their effectiveness in alleviating emotional problems. Scientists continue to revisit different psychedelics such as LSD, magic mushrooms and other therapeutics for a range of mental ailments. Research is in full swing with the announcement from Johns Hopkins on its development of the Center for Psychedelic and Consciousness Research. With a $17 million commitment for planned studies, the research will further help in normalizing psychedelics. Therefore, the shroom boom has well and truly arrived, and investors should seriously consider adding psychedelic stocks to their portfolios.

Investor interest in psychedelics is on the rise as high-profile executives and celebrities are investing in the sector’s future. With such much interest in alternative psychedelic medicine, analysts believe that the sector could bring in over $6.85 billion by 2027. However, government support and widespread legalization are essential for its rapid advancement. With the recent legalization of psychedelics in various states, it won’t be long when they line up pharmacy aisles.

It is imperative to invest in psychedelic stocks that are needle-movers having the most potential for sustained success. Here are three that stand out right now:

  • Champignon Brands (OTCMKTS:SHRMF)
  • Mind Medicine (OTCMKTS:MMEDF)
  • Hollister Biosciences (OTCMKTS:HSTRF)

Psychedelic Stocks to Buy: Champignon Brands (SHRMF)

Source: local_doctor / Shutterstock.com

Champignon Brands is among the first movers in the psychedelic medicine field and it completed its IPO earlier this year. It is engaged in the production of novel medications, specifically medicinal mushroom products, which aim to treat a variety of mental health problems. It boasts one of the strongest research teams led by its Special Advisory Committee, working diligently to provide high-quality data to its production team. Hence, SHRMF stock is among the hottest investments in the burgeoning psychedelics field.

It has been a busy 2020 for the Vancouver-based company. In April, it announced that it would be acquiring clinic operator AltMed Capital Corp, aiming at opening several subspecialty therapeutic clinics across the U.S. Additionally, the deal also provides several intellectual properties in developing novel medicines. Moreover, Champignon is also looking to open clinics for psychedelics, such as ketamine, psilocybin and MDMA throughout the North American continent.

It has six current trials in Phase I and pre-clinical stages collectively and seven patents pursuing ketamine/psilocybin solutions. To better reflect its scientific alignments, it is proposing a name change to Apotheosis Scientific Ltd. Therefore, with so much on its plate, the company can become a juggernaut among psychedelic stocks.

Mind Medicine (MMEDF)

Business psychology concept and wealth thinking

Source: Shutterstock

MindMedicine is one of the largest biotechs involved in psychedelic drugs’ clinical development tackling mental health troubles. With the success of its Compass Pathways IPO, it is now looking to enlist on the U.S. stock exchange. It would become the second pure-play to be listed on Nasdaq. Hence, MMEDF stock is one of the top investments in the sector with massive potential.

It has three on-going clinical trials, which can be major

Read more

Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients, in order to identify genetic alterations driving disease and potentially reveal previously unidentified therapies for treatment. The initiative, which also includes a collaboration between Weill Cornell Medicine, NewYork-Presbyterian Hospital, and the New York Genome Center (NYGC), aims to evaluate the diagnostic potential of whole-genome sequencing at scale, which allows the interrogation of the full genome sequence of a patient’s DNA. The goal is to better understand health problems and potential disease risks of individual patients, and to design more effective treatments, including the choice of specific drugs and their dosing.

Investigators will study the feasibility and viability of large-scale implementation of whole-genome sequencing within an academic medical center that is part of a major metropolitan health care system in the United States. Whole-genome sequencing has already been shown to improve patient care and disease prevention in specific clinical contexts, but few systems have deployed whole-genome sequencing across multiple care pathways. Weill Cornell Medicine, through its Caryl and Israel Englander Institute for Precision Medicine, and NewYork-Presbyterian/Weill Cornell Medical Center, which have applied this precision medicine approach to investigate cancer’s molecular underpinnings since 2015, will be among the first medical institutions to examine the feasibility of large-scale whole-genome sequencing across multiple diseases. In addition to revealing the role individual genes play in disease and therapeutic responses, the study could also yield promising new avenues for scientific inquiry.

Under the initiative, which originates from Weill Cornell Medicine’s Englander Institute for Precision Medicine, doctors at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center will offer qualifying patients the option to have their genomes sequenced as part of their diagnostic workups. NYGC will leverage its high-throughput whole-genome sequencing clinical sequencing expertise to investigate patients’ DNA, using Illumina’s patented Next-Generation Sequencing technology. NYGC was the first sequencing center in the country to gain regulatory approval for clinical whole-genome sequencing tests for genetic diseases and cancer from the New York State Department of Health Clinical Laboratory Evaluation Program. Board-certified molecular geneticists at NYGC will interpret and share the results with ordering physicians, who will then share them with their patients. The initiative will focus on the disease areas of oncology, cardiovascular, metabolic and neurodegenerative diseases. This first phase will inform the next steps to expand infrastructure to support more widespread testing in years to come.  

“We are committed to expanding whole-genome sequencing to cancer and other common diseases more broadly, so that the approach can eventually become a routine part of healthcare, an essential source of data for biomedical research and, importantly, enhance patient care,” said Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, who also leads joint precision medicine efforts at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “This project and the network of participating

Read more

Bioelectric Medicine Market Size, Share Report 2020 Shipments, Price, Revenue and Gross profit till 2025 With Impact of COVID-19

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (The Expresswire) —
“Final Report will add the analysis of the impact of COVID-19 on this industry.”

“Bioelectric Medicine Market” research report offers the breakdown of the industry by market size, rate of development, key companies, counties, product selections and application. The Bioelectric Medicine Market Report delivers current state, openings, limits, drivers and also the evolution forecasts of the market by 2025. Profound investigation about Bioelectric Medicine market standing, enterprise competition outline, welfares and drawbacks of enterprise stock, Bioelectric Medicine industry development trends, regional industrial layout features and economics policies, industry News and Strategies by Regions has additionally been enclosed.

Get a Sample Copy of the Report at- https://www.industryresearch.co/enquiry/request-sample/16705148

In Regional Analysis, the Bioelectric Medicine market is also categorised into North America, Europe, China, Japan, the middle East, India, South America, Others. North America, Europe is expected to account for a distinguished share, in terms of price and extent, of the Bioelectric Medicine market throughout the forecast length. The Bioelectric Medicine market within the Asia Pacific is projected to extend throughout the forecast period. Evolving markets that include China and Asian country are expected to play a significant position within the boom in producing the surrounding area.

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

To Understand the Impact of COVID-19 on Bioelectric Medicine Market: – https://www.industryresearch.co/enquiry/request-covid19/16705148

Bioelectric Medicine market report provides in-depth data about company Profiles, Bioelectric Medicine launching and Market Positioning, their Production, Value, Price, ratio and Target Customers. Research report contains data about following major players in Bioelectric Medicine market, which strategically profile the key players and comprehensively analyse their growth strategies and market segmentation:

Key players in the global Bioelectric Medicine market covered in report:

● Nevro ● Second Sight Medical Products ● Sonova Holding ● St. Jude Medical ● Medtronic ● Cochlear ● Electrocore ● Boston Scientific Corporation ● Livanova ● Biotronik

On the basis of types, the Bioelectric Medicine market from 2015 to 2025 is primarily split into:

● Implantable Cardioverter Defibrillators ● Cardiac Pacemakers ● Spinal Cord Stimulators ● Cochlear Implants ● Deep Brain Stimulators ● Transcutaneous Electrical Nerve Stimulators ● Vagus Nerve Stimulators ● Sacral Nerve Stimulators ● Retinal Implants ● Other Electrical Stimulators

On the basis of applications, the Bioelectric Medicine market from 2015 to 2025 covers:

● Hospitals ● Research Institutes ● Individual Users

Inquire or Share Your Questions If Any Before the Purchasing This Report- https://www.industryresearch.co/enquiry/pre-order-enquiry/16705148

Bioelectric Medicine Market Report Scope:

The In-depth industry chain includes analysis value chain analysis, porter five forces model analysis and cost structure analysis. This Bioelectric Medicine Market report describes present situation, historical background and future forecast. It Comprehensive data showing Bioelectric Medicine sale, consumption, trade statistics, and prices in the recent years are provided. The Bioelectric Medicine report indicates a wealth of information on Bioelectric Medicine vendors. Bioelectric Medicine Market forecast for next five years, including Market volumes

Read more